Home
Market Research Reports
Healthcare, Pharmaceuticals and Medical devices
Vulvodynia Treatment Market

An Incisive, In-depth Analysis on the Vulvodynia Treatment Market

This study offers a comprehensive, 360 degree analysis on the Vulvodynia Treatment market, bringing to fore insights that can help stakeholders identify the opportunities as well as challenges. It tracks the global Vulvodynia Treatment market across key regions, and offers in-depth commentary and accurate quantitative insights. The study also includes incisive competitive landscape analysis, and provides key recommendations to market players on winning imperatives and successful strategies.

Request a sample

Ask An Analyst

Request Special Price

Request Methodology

There is an increasing tendency of women who have observed chronic vulvar pain once in a lifetime. If the pain is persistent for more than three months and has no apparent cause, it is called vulvodynia. It is estimated that 16% of women in the U.S. will have Vulvodynia at some point in their lives. According to the National Center for Biotechnology Information, U.S. National Library of Medicine, 17.9% of women reported symptoms suggestive of past Vulvodynia in 2013. Based on an analysis, 101,007 women in the 4-county area are estimated to have vulvar pain consistent with Vulvodynia, with another 218,219 having a history of such pain that has since resolved. As a result of these factors, the demand for the drugs is constantly rising. The drug type and its use is measured by the level of pain that is caused of vulvodynia. Although it is a chronic disease, at times even the minutest of pain can cause depression and anxiety among women.

Anticonvulsant to be the most used drug

Anticonvulsant is a type of medication that is used for controlling seizures or stop an ongoing series of seizures (convulsions). In Vulvodynia treatment, anticonvulsant is the most prescribed drug. Gabapentin is most reliable anticonvulsant drug available in vulvodynia treatment. Gabapentin is a drug which has long been recognized in chronic pain management as an effective way of curing pain. It contains tablets taken by mouth and works well for pain related to the nerve. The tablets are prescribed for a number of conditions impacting the central nervous system and they influence pain at the level of the spinal cord. Pregabalin is another anticonvulsant drug. It is very similar to gabapentin; however, it is reported to have fewer side effects and is possibly more operative.

Tricyclic antidepressant to rise in consumption

Tricyclic antidepressants (TCAs) are a class of medications that are used primarily as antidepressants. These can be prescribed by your doctor in doses lower than those used to treat depression. The drugs are used because they alter the way in which the nerve fibres transmit the sensation of pain, not because the doctor thinks it's all in your mind. It is often necessary to continue with treatment for 3-6 months. Examples of tablets include amitriptyline, nortriptyline and dothiepin. Other antidepressants namely venlafaxine can also be tried. As the treatment of vulvodynia is mainly centred at placebo, antidepressants are the first of form of medical treatments given to a patient in case of minor pains.

Use of local anaesthetic to rise globally

Local anaesthetics are generally applied externally to the skin. This medication originates in a form of gel or cream. They may be used before sexual intercourse to provide short-term pain relief, or they can be used for extended periods. Local anaesthetic is used topically to introitus, which decrease hypersensitivity. This medication need to apply before intercourse or nightly on a cotton ball in the introitus. Lidocaine gel or cream is considered to be the best local anaesthetic cream or gel for vulvodynia.

Global Healthcare Sector Outlook

Despite the economic and political uncertainty in the recent past, the global healthcare industry has been receiving positive nudges from reformative and technological disruptions in medical devices, pharmaceuticals and biotech, in-vitro diagnostics, and medical imaging. Key markets across the world are facing a massive rise in demand for critical care services that are pushing global healthcare spending levels to unimaginable limits.

A rapidly multiplying geriatric population; increasing prevalence of chronic ailments such as cancer and cardiac disease; growing awareness among patients; and heavy investments in clinical innovation are just some of the factors that are impacting the performance of the global healthcare industry. Proactive measures such as healthcare cost containment, primary care delivery, innovation in medical procedures (3-D printing, blockchain, and robotic surgery to name a few), safe and effective drug delivery, and well-defined healthcare regulatory compliance models are targeted at placing the sector on a high growth trajectory across key regional markets.

Parent Indicators Healthcare

Current expenditure on health, % of gross domestic product
Current expenditure on health, per capita, US$ purchasing power parities (current prices, current PPPs)
Annual growth rate of current expenditure on health, per capita, in real terms
Out-of-pocket expenditure, % of current expenditure on health
Out-of-pocket expenditure, per capita, US$ purchasing power parity (current prices, current PPPs)
Physicians, Density per 1000 population (head counts)
Nurses, Density per 1000 population (head counts)
Total hospital beds, per 1000 population
Curative (acute) care beds, per 1000 population
Medical technology, Magnetic Resonance Imaging units, total, per million population
Medical technology, Computed Tomography scanners, total, per million population

Research Methodology

FMI utilizes a triangulation methodology that is primarily based on experimental techniques such as patient-level data, to obtain precise market estimations and insights on Molecule and Drug Classes, API Formulations and preferred modes of administration. Bottom-up approach is always used to obtain insightful data for the specific country/regions. The country specific data is again analysed to derive data at a global level. This methodology ensures high quality and accuracy of information.

Secondary research is used at the initial phase to identify the age specific disease epidemiology, diagnosis rate and treatment pattern, as per disease indications. Each piece of information is eventually analysed during the entire research project which builds a strong base for the primary research information.

Primary research participants include demand-side users such as key opinion leaders, physicians, surgeons, nursing managers, clinical specialists who provide valuable insights on trends and clinical application of the drugs, key treatment patterns, adoption rate, and compliance rate.

Quantitative and qualitative assessment of basic factors driving demand, economic factors/cycles and growth rates and strategies utilized by key players in the market is analysed in detail while forecasting, in order to project Year-on-Year growth rates. These Y-o-Y growth projections are checked and aligned as per industry/product lifecycle and further utilized to develop market numbers at a holistic level.

On the other hand, we also analyse various companies annual reports, investor presentations, SEC filings, 10k reports and press release operating in this market segment to fetch substantial information about the market size, trends, opportunity, drivers, restraints and to analyse key players and their market shares. Key companies are segmented at Tier level based on their revenues, product portfolio and presence.

Standard Report Structure

Executive Summary
Market Definition
Macro-economic analysis
Parent Market Analysis
Market Overview
Forecast Factors
Segmental Analysis and Forecast
Regional Analysis
Competition Analysis

Market Taxonomy

The vulvodynia treatment market has been segmented on the following:

Drug Class	Mode of Administration	Distribution Channel	Region
Local Anesthetic Anticonvulsant Tricyclic Antidepressant Hormones Serotonin-norepinephrine Reuptake Inhibitors (SNRI) Nerve Block Others	Oral Topical Injection	Hospital Pharmacies Retail Pharmacies Drug Store Online Pharmacies	North America Latin America Western Europe Eastern Europe APEJ Japan MEA

Specific Report Inputs

The analyst has checked the prevalence of vulvodynia among the women of 18 to 45 years of age. The main countries in every region have been gauged to check the prevalence rate in every country. The co-morbidity rate has also been considered country-wise. The annual treatment cost along with the volume consumed has been taken into consideration to come to the data in the report.